litlas
Log inCreate account

Gregory A. Otterson

Active 1995–2025

106
Papers
27,404
Citations
79
h-index
104
i10-index

Citations

Citations per year for Gregory A. Otterson1983: 1 citations1990: 1 citations1993: 1 citations1994: 1 citations1995: 14 citations1996: 26 citations1997: 31 citations1998: 49 citations1999: 66 citations2000: 37 citations2001: 47 citations2002: 52 citations2003: 54 citations2004: 70 citations2005: 67 citations2006: 66 citations2007: 71 citations2008: 76 citations2009: 75 citations2010: 67 citations2011: 93 citations2012: 103 citations2013: 109 citations2014: 120 citations2015: 165 citations2016: 223 citations2017: 263 citations2018: 287 citations2019: 1,214 citations2020: 1,431 citations2021: 1,411 citations2022: 1,054 citations2023: 760 citations2024: 1,224 citations2025: 427 citations2026: 12 citations1984–1989: no citations, so these years are not shown1991–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,471 citing papers, 24.9% of this breakdownChina: 2,603 citing papers, 18.7% of this breakdownItaly: 759 citing papers, 5.4% of this breakdownGermany: 603 citing papers, 4.3% of this breakdownUnited Kingdom: 598 citing papers, 4.3% of this breakdownFrance: 574 citing papers, 4.1% of this breakdownJapan: 573 citing papers, 4.1% of this breakdownSpain: 453 citing papers, 3.2% of this breakdownCanada: 414 citing papers, 3% of this breakdownSouth Korea: 345 citing papers, 2.5% of this breakdownAustralia: 324 citing papers, 2.3% of this breakdownSwitzerland: 307 citing papers, 2.2% of this breakdown
0%24.9%Other 21%

Institutions

Fields

  • Medicine69.3%
  • Biochemistry, Genetics and Molecular Biology24.4%
  • Immunology and Microbiology2.7%
  • Neuroscience0.8%
  • Engineering0.6%
  • Computer Science0.5%
  • Other1.7%

Topics

  • Cancer Immunotherapy and Biomarkers11.8%
  • Lung Cancer Treatments and Mutations10.1%
  • Lung Cancer Diagnosis and Treatment5.7%
  • Lung Cancer Research Studies5.5%
  • Cancer Genomics and Diagnostics4.1%
  • Immunotherapy and Immune Responses2.3%
  • Other60.5%

Coauthors

All papers

Open in search
  1. Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm M. DeCamp, Thomas J. Dilling, Jonathan E. Dowell, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Jose M. Pacheco, Sandip Pravin Patel, Gregory J. Riely, Jonathan W. Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2022 cited by 1,419

  2. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    Authors: Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak A. Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Chang Han, Joseph D. Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith E. Nathan, Luis Paz‐Ares - New England Journal of Medicine 2018 cited by 3,137

  3. NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023

    Authors: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm M. DeCamp, Thomas J. Dilling, Jonathan E. Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip Pravin Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan W. Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2023 cited by 483

  4. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

    Authors: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Jonathan E. Dowell, Scott Gettinger, Matthew A. Gubens, Aparna Hegde, Mark Hennon, Rudy P. Lackner, Michael Lanuti, Ticiana Leal, Jules Lin, Billy W. Loo, Christine M. Lovly, Renato Martins, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip Pravin Patel, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Jane Yanagawa, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2021 cited by 1,006

  5. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

    Authors: Bairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash, Patrick M. Forde, Josephine Feliciano, Kristen A. Marrone, David S. Ettinger, Christine L. Hann, Julie R. Brahmer, Biagio Ricciuti, Dwight H. Owen, Yukihiro Toi, Paul R. Walker, Gregory A. Otterson, Sandip H. Patel, Shunichi Sugawara, Jarushka Naidoo - JAMA Oncology 2020 cited by 489

  6. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Authors: Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Płużański, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Żurawski, Aurelia Alexandru, A. Vergnenègre, Judith Raimbourg, Kynan Feeney, Sang‐We Kim, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck - Journal of Thoracic Oncology 2021 cited by 322

  7. First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

    Authors: Neal Ready, Matthew D. Hellmann, Mark M. Awad, Gregory A. Otterson, Martin Gutierrez, Justin F. Gainor, Hossein Borghaei, Jacques Jolivet, Leora Horn, Mihaela Mates, Julie R. Brahmer, Ian Rabinowitz, Pavan S. Reddy, Jason Chesney, James Michael Orcutt, David R. Spigel, Martin Reck, Kenneth J. O’Byrne, Luis Paz‐Ares, Wenhua Hu, Kim E. Zerba, Xuemei Li, Brian Lestini, William J. Geese, Joseph D. Szustakowski, George Green, Chang Han, Suresh S. Ramalingam - Journal of Clinical Oncology 2019 cited by 596

  8. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

    Authors: Gregory J. Riely, Egbert F. Smit, Myung‐Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne S. Tsao, Melissa L. Johnson, Francesco Gelsomino, Raymond M. Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo‐Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith D. Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson - Journal of Clinical Oncology 2023 cited by 114

  9. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

    Authors: Alexander Drilon, Salvatore Siena, Rafał Dziadziuszko, Fabrice Barlési, Matthew Krebs, Alice T. Shaw, Filippo de Braud, Christian Rolfo, Myung‐Ju Ahn, Jürgen Wolf, Takashi Seto, Byoung Chul Cho, Manish R. Patel, Chao‐Hua Chiu, Thomas John, Kōichi Goto, Christos S. Karapetis, Hendrick-Tobias Arkenau, Sang-We Kim, Yuichiro Ohe, Yu Li, Young Kwang Chae, Christine H. Chung, Gregory A. Otterson, Haruyasu Murakami, Chia‐Chi Lin, Daniel Shao-Weng Tan, Hans Prenen, Todd Riehl, Edna Chow‐Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, Robert C. Doebele - The Lancet Oncology 2019 cited by 537

  10. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

    Authors: Alexander Drilon, Jeffrey W. Clark, Jared Weiss, Sai‐Hong Ignatius Ou, D. Ross Camidge, Benjamin Solomon, Gregory A. Otterson, Liza C. Villaruz, Gregory J. Riely, Rebecca S. Heist, Mark M. Awad, Geoffrey I. Shapiro, Miyako Satouchi, Toyoaki Hida, Hidetoshi Hayashi, Danielle Murphy, Sherry Wang, Sherry Li, Tiziana Usari, Keith D. Wilner, Paul K. Paik - Nature Medicine 2020 cited by 393

  11. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

    Authors: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm M. DeCamp, Thomas J. Dilling, M.C. Dobelbower, Robert C. Doebele, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Ticiana Leal, Leah J. Leisch, Rogerio Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Steven Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2017 cited by 1,325

  12. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

    Authors: Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, Keunchil Park, Dae Ho Lee, İrfan Çiçin, Perran Fulden Yumuk, Francesco Orlandi, Ticiana Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te‐Chun Hsia, Gregory A. Otterson, Lu Xu, Bilal Piperdi, Ayman Samkari, Martin Reck, for the KEYNOTE-598 Investigators - Journal of Clinical Oncology 2021 cited by 253

  13. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Authors: Naiyer A. Rizvi, Julien Mazières, David Planchard, Thomas E. Stinchcombe, Grace K. Dy, Scott Antonia, Leora Horn, H. Léna, Elisa Minenza, B. Mennecier, Gregory A. Otterson, Luis T. Campos, David R. Gandara, Benjamin Levy, Suresh Nair, Gérard Zalcman, Jürgen Wolf, Pierre‐Jean Souquet, Editta Baldini, Federico Cappuzzo, C. Chouaïd, Afshin Dowlati, Rachel E. Sanborn, Ariel López-Chávez, Christian Grohé, Rudolf M. Huber, Christopher Harbison, Christine Baudelet, Brian Lestini, Suresh S. Ramalingam - The Lancet Oncology 2015 cited by 1,429

  14. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

    Authors: Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy, Mohammad Shahrokh Esfahani, Aaron M. Newman, Henry J. Haringsma, David M. Kurtz, Henning Stehr, Florian Scherer, Chris Karlovich, Thomas C. Harding, Kathleen A. Durkin, Gregory A. Otterson, W. Thomas Purcell, D. Ross Camidge, Jonathan W. Goldman, Lecia V. Sequist, Zofia Piotrowska, Heather A. Wakelee, Joel W. Neal, Ash A. Alizadeh, Maximilian Diehn - Nature Communications 2016 cited by 659

  15. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

    Authors: Alexander Drilon, Chao‐Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lü, Myung‐Ju Ahn, Matthew Krebs, Stephen V. Liu, Thomas John, Gregory A. Otterson, Daniel S.W. Tan, Tejas Patil, Rafał Dziadziuszko, Erminia Massarelli, Takashi Seto, Robert C. Doebele, Bethany Pitcher, Nino Kurtsikidze, Sebastian Heinzmann, Salvatore Siena - JTO Clinical and Research Reports 2022 cited by 113

  16. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

    Authors: David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, M.C. Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana Leal, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Sandip Pravin Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, OCN, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2019 cited by 1,005

  17. Advances in epigenetic therapeutics with focus on solid tumors

    Authors: Ning Jin, Tiffany L. George, Gregory A. Otterson, Claire F. Verschraegen, Haitao Wen, David P. Carbone, James G. Herman, Erin M. Bertino, Kai He - Clinical Epigenetics 2021 cited by 125

  18. Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model

    Authors: Nathan A. Pennell, Alex Mutebi, Zheng‐Yi Zhou, Marie Louise Ricculli, Wenxi Tang, Helen Wang, Annie Guérin, Tom Arnhart, Anand A. Dalal, Medha Sasané, Kevin Y. Wu, Kenneth W. Culver, Gregory A. Otterson - JCO Precision Oncology 2019 cited by 222

  19. Crizotinib in Patients With MET-Amplified NSCLC

    Authors: D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark, Sai‐Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I. Shapiro, Mark A. Socinski, Danielle Murphy, Umberto Conte, Yiyun Tang, Sherry Wang, Keith D. Wilner, Liza C. Villaruz - Journal of Thoracic Oncology 2021 cited by 168

  20. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

    Authors: Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam, Leora Horn, Javier de Castro, Adam Płużański, Marco Angelo Burgio, Marina Chiara Garassino, Laura Q.M. Chow, Scott Gettinger, Lucio Crinò, David Planchard, Charles Butts, Alexander Drilon, Joanna Wójcik-Tomaszewska, Gregory A. Otterson, Shruti Agrawal, Ang Li, John R. Penrod, Julie R. Brahmer - The Lancet Oncology 2019 cited by 365

  21. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

    Authors: David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, M.C. Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogério Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M.W. Pisters, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, James Stevenson, Steven Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2016 cited by 738

  22. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer

    Authors: Dwight H. Owen, Lai Wei, Erin M. Bertino, Thomas Edd, Miguel A. Villalona‐Calero, Kai He, Peter G. Shields, David P. Carbone, Gregory A. Otterson - Clinical Lung Cancer 2018 cited by 147

  23. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

    Authors: Hamzah Abu‐Sbeih, Faisal S. Ali, Abdul Rafeh Naqash, Dwight H. Owen, Sandipkumar Patel, Gregory A. Otterson, Kari Kendra, Biagio Ricciuti, Rita Chiari, Andrea De Giglio, Joseph Sleiman, Pauline Funchain, Wills Beatriz, Jiajia Zhang, Jarushka Naidoo, Jessica Philpott, Jianjun Gao, Sumit K. Subudhi, Yinghong Wang - Journal of Clinical Oncology 2019 cited by 197

  24. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival

    Authors: Abdul Miah, Gabriel Tinoco, Songzhu Zhao, Lai Wei, Andrew Johns, Sandip Pravin Patel, Mingjia Li, Madison Grogan, Gabrielle Lopez, Marium Husain, Rebecca Hoyd, Khalid Mumtaz, Alexa Meara, Erin M. Bertino, Kari Kendra, Daniel Spakowicz, Gregory A. Otterson, Carolyn J. Presley, Dwight H. Owen - Journal of Cancer Research and Clinical Oncology 2022 cited by 40